Asundexian Shows 26% Stroke Risk Reduction in Phase III
Dateline – New Orleans, USA, Feb. 5, 2026 — Bayer announced that its investigational oral Factor XIa inhibitor asundexian...
Phase III Clinical Trial
Advertisement
FDA Approves RHA® Dynamic Volume for Midface Contour Deficits
Nashville, Tenn., January 13, 2026 — Revance and Teoxane announced that the U.S. Food and Drug Administration has approved...
Cardiol Reaches 50% Enrollment in Phase III MAVERIC Trial
Toronto, Jan. 13, 2026 — Cardiol Therapeutics Inc. announced that it has surpassed the 50% patient enrollment milestone in...
Greenwich Reports 80% Recurrence Reduction in FLAMINGO-01
STAFFORD, Texas — December 15, 2025 — Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, announced a preliminary analysis from...
Mabwell’s 9MW3011 Achieves Positive Phase III Results in Moderate-to-Severe Plaque Psoriasis
SHANGHAI, CHINA – November 11, 2025 — Mabwell (688062.SH), an innovative biopharmaceutical company specializing in biologics for major diseases,...
Advertisements
Baxdrostat Achieves Primary Endpoint in Phase III Trial for rHTN
SLondon, UK – October 7, 2025 – AstraZeneca announced that Baxdrostat met the primary endpoint in the Bax24 Phase...
Advertisement
